Please use this identifier to cite or link to this item:
Title: Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Austin Authors: Hendry, Shona;Salgado, Roberto;Gevaert, Thomas;Russell, Prudence A;John, Tom;Thapa, Bibhusal ;Christie, Michael;van de Vijver, Koen;Estrada, M V;Gonzalez-Ericsson, Paula I;Sanders, Melinda;Solomon, Benjamin;Solinas, Cinzia;Van den Eynden, Gert G G M;Allory, Yves;Preusser, Matthias;Hainfellner, Johannes;Pruneri, Giancarlo;Vingiani, Andrea;Demaria, Sandra;Symmans, Fraser;Nuciforo, Paolo;Comerma, Laura;Thompson, E A;Lakhani, Sunil;Kim, Seong-Rim;Schnitt, Stuart;Colpaert, Cecile;Sotiriou, Christos;Scherer, Stefan J;Ignatiadis, Michail;Badve, Sunil;Pierce, Robert H;Viale, Giuseppe;Sirtaine, Nicolas;Penault-Llorca, Frederique;Sugie, Tomohagu;Fineberg, Susan;Paik, Soonmyung;Srinivasan, Ashok;Richardson, Andrea;Wang, Yihong;Chmielik, Ewa;Brock, Jane;Johnson, Douglas B;Balko, Justin;Wienert, Stephan;Bossuyt, Veerle;Michiels, Stefan;Ternes, Nils;Burchardi, Nicole;Luen, Stephen J;Savas, Peter;Klauschen, Frederick;Watson, Peter H;Nelson, Brad H;Criscitiello, Carmen;O'Toole, Sandra;Larsimont, Denis;de Wind, Roland;Curigliano, Giuseppe;André, Fabrice;Lacroix-Triki, Magali;van de Vijver, Mark;Rojo, Federico;Floris, Giuseppe;Bedri, Shahinaz;Sparano, Joseph;Rimm, David;Nielsen, Torsten;Kos, Zuzana;Hewitt, Stephen;Singh, Baljit;Farshid, Gelareh;Loibl, Sibylle;Allison, Kimberly H;Tung, Nadine;Adams, Sylvia;Willard-Gallo, Karen;Horlings, Hugo M;Gandhi, Leena;Moreira, Andre;Hirsch, Fred;Dieci, Maria V;Urbanowicz, Maria;Brcic, Iva;Korski, Konstanty;Gaire, Fabien;Koeppen, Hartmut;Lo, Amy;Giltnane, Jennifer;Rebelatto, Marlon C;Steele, Keith E;Zha, Jiping;Emancipator, Kenneth;Juco, Jonathan W;Denkert, Carsten;Reis-Filho, Jorge;Loi, Sherene;Fox, Stephen B
Affiliation: The Sir Peter MacCallum Department of Oncology, Departments of Pathology and Medicine, University of Melbourne
Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville
Department of Anatomical Pathology, St Vincent’s Hospital Melbourne, Fitzroy
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Bundoora
Centre for Clinical Research and School of Medicine, The University of Queensland
Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane
The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst
Australian Clinical Labs, Bella Vista
Directorate of Surgical Pathology, SA Pathology, Australia
Discipline of Medicine, Adelaide University, Adelaide, Australia
Department of Surgical Oncology, Netherlands Cancer Institute
Department of Pathology and Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
Université Paris-Est
Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil
Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay
INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif
Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre
Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre
University of Auvergne UMR1240, Clermont-Ferrand, France
Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna
Institute of Pathology, Medical University of Graz, Austria
European Institute of Oncology
Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan
Department of Surgery, Oncology and Gastroenterology, University of Padova
Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona
Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain
Department of Pathology and TCRU, GZA
Department of Pathology, GZA Ziekenhuizen, Antwerp
Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven
Department of Pathology, University Hospital Leuven, Leuven, Belgium
Department of Pathology, AZ Klina, Brasschaat
Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk
Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet
European Organisation for Research and Treatment of Cancer (EORTC) Headquarters
Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Department of Surgery, Kansai Medical School, Hirakata, Japan
Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea
Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center
Institute of Oncology, Gliwice Branch, Gliwice, Poland
Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg
Institute of Pathology, Charité Universitätsmedizin Berlin
VMscope GmbH, Berlin
German Breast Group GmbH, Neu-Isenburg, Germany
Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
Department of Biochemistry and Microbiology, University of Victoria, Victoria
Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC
Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar
Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center
Warren Alpert Medical School of Brown University, Providence
National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA
Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University
Department of Medicine, Vanderbilt University Medical Centre
Vanderbilt Ingram Cancer Center, Nashville
Department of Pathology, Yale University School of Medicine, New Haven
Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine
Montefiore Medical Center
The Albert Einstein College of Medicine, Bronx, NY
Department of Pathology, Brigham and Women’s Hospital
Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center
Harvard Medical School
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute, Boston, MA
Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN
Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA
Department of Pathology, New York University Langone Medical Centre
New York University Medical School
Perlmutter Cancer Center
Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University
Department of Pathology, Memorial Sloan-Kettering Cancer Center
Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX
Pathology Department, Stanford University Medical Centre, Stanford
Department of Pathology, Stanford University, Palo Alto
Department of Pathology, School of Medicine, University of California, San Diego
Research Pathology, Genentech Inc., South San Francisco, CA
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda
Translational Sciences, MedImmune, Gaithersberg, MD
Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover
Translational Medicine, Merck & Co. Inc., Kenilworth, NJ
Issue Date: Sep-2017
Publication information: Advances in anatomic pathology 2017; 24(5): 235-251
Abstract: Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
DOI: 10.1097/PAP.0000000000000162
Journal: Advances in anatomic pathology
PubMed URL: 28777142
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 24, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.